BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264-1274. [PMID: 12181251 DOI: 10.1093/annonc/mdf253] [Cited by in Crossref: 215] [Cited by in F6Publishing: 168] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Doan TN, Kirkpatrick CMJ, Walker P, Slavin MA, Ananda-rajah MR, Morrissey CO, Urbancic KF, Grigg A, Spencer A, Szer J, Seymour JF, Kong DCM. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. J Antimicrob Chemother 2016;71:497-505. [DOI: 10.1093/jac/dkv343] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
2 Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P. Lymphoma – Emerging realities in sub-Saharan Africa. Transfusion and Apheresis Science 2010;42:141-50. [DOI: 10.1016/j.transci.2010.01.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. Br J Haematol 2020;189:661-71. [PMID: 32017050 DOI: 10.1111/bjh.16425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
4 Koechli V, Klaeser B, Banz Y, Mueller BU, Pabst T. Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma. Leukemia Research 2015;39:307-10. [DOI: 10.1016/j.leukres.2014.12.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Atallah-Yunes SA, Murphy DJ, Noy A. HIV-associated Burkitt lymphoma. Lancet Haematol 2020;7:e594-600. [PMID: 32735838 DOI: 10.1016/S2352-3026(20)30126-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
6 Ahmed SO, Sureda A, Aljurf M. The role of hematopoietic SCT in adult Burkitt lymphoma. Bone Marrow Transplant 2013;48:617-29. [PMID: 22858508 DOI: 10.1038/bmt.2012.129] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Finch DA, Wilson MS, O'Dwyer ST. Successful Management of Jejunal Perforation in Burkitt's Lymphoma: A Case Report. Case Rep Surg 2012;2012:230538. [PMID: 23024879 DOI: 10.1155/2012/230538] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004;10:579-90. [PMID: 15319770 DOI: 10.1016/j.bbmt.2004.05.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
9 Baryakh EA, Tyurina NG, Vorobyev VI, Gemdzhyan EG, Mangasarova YK, Klyasova GA, Kovrigina AM, Obukhova TN, Zvonkov EE, Vernyuk MA, Chervontseva AM, Polyakov YY, Misyurina АЕ, Valiev TT, Zherebtsova VA, Magomedova AU, Galstyan GM, Yatskov KV, Nesterova ES, Vorobyev AI, Kravchenko SK. [Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience]. Ter Arkh 2015;87:4-14. [PMID: 26390720 DOI: 10.17116/terarkh20158774-14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. Semin Oncol 2009;36:381-418. [PMID: 19835736 DOI: 10.1053/j.seminoncol.2009.07.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
11 Papachristos A, Pippa N, Ioannidis K, Sivolapenko G, Demetzos C. Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives. J Liposome Res 2015;25:166-73. [PMID: 25148295 DOI: 10.3109/08982104.2014.950277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K, Slack GW, Abou Mourad Y, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Sanford DS, Sutherland HJ, Tucker T, Toze CL, Sehn LH, Broady R, Gerrie AS. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. Br J Haematol 2018;181:782-90. [DOI: 10.1111/bjh.15262] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kim HD, Cho H, Kim S, Lee K, Kang EH, Park JS, Park CS, Huh J, Ryu JS, Lee SW, Yoon DH, Kim SJ, Ko YH, Kim WS, Suh C. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels. Cancer Res Treat 2021;53:847-56. [PMID: 33332932 DOI: 10.4143/crt.2020.1060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Place AE, Frederick NN, Sallan SE. Therapeutic approaches to haematological malignancies in adolescents and young adults. Br J Haematol 2014;164:3-14. [PMID: 24007213 DOI: 10.1111/bjh.12556] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
15 Gupta S, Alexander S, Pole JD, Sutradhar R, Crump M, Nagamuthu C, Baxter NN, Nathan PC. Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2021. [PMID: 34599525 DOI: 10.1111/bjh.17862] [Reference Citation Analysis]
16 Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013;19:173-9. [PMID: 23200705 DOI: 10.1016/j.bbmt.2012.11.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
17 Mcmillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 2005;131:13-21. [DOI: 10.1111/j.1365-2141.2005.05703.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
18 van Imhoff GW, van der Holt B, Mackenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MHH, van 't Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MHJ, Raemaekers JMM, Sonneveld P, Meulendijks LAMH, Kluin PM, Kluin-nelemans HC, Verdonck LF. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005;19:945-52. [DOI: 10.1038/sj.leu.2403733] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
19 Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-25. [PMID: 24224624 DOI: 10.1056/NEJMoa1308392] [Cited by in Crossref: 219] [Cited by in F6Publishing: 86] [Article Influence: 24.3] [Reference Citation Analysis]
20 Nosho K, Shitani M, Takahashi F, Ikeda Y, Goto A, Yamamoto H, Arimura Y, Ishida T, Endo T, Sato M. A case of primary gastric Burkitt-like lymphoma in the early stage diagnosed by endoscopic mucosal resection. Int J Colorectal Dis. 2006;21:188-189. [PMID: 15668784 DOI: 10.1007/s00384-004-0701-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Haralambieva E, Schuuring E, Rosati S, van Noesel C, Jansen P, Appel I, Guikema J, Wabinga H, Bleggi-Torres LF, Lam K. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer. 2004;40:10-18. [PMID: 15034863 DOI: 10.1002/gcc.20009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
22 Woodcock H, Nelson M. Burkitt's non-Hodgkins lymphoma presenting as facial nerve palsy in HIV-positive patients. Int J STD AIDS 2011;22:112-4. [DOI: 10.1258/ijsa.2010.010293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
23 Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Ann Oncol 2013;24:3076-81. [PMID: 24146219 DOI: 10.1093/annonc/mdt414] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
24 Astrow AB, Tarabay G, Salerno VE, Cook WA, Lin R, Lascher S, Li Z, Mazumder A, Halperin I, Cho J, Jaffar Z, Mclaughlin M, Blum RH, Kempin SJ. Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: the role for short course intensive chemotherapy. Hematol Oncol 2003;21:131-40. [DOI: 10.1002/hon.715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
25 Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final Results of Cancer and Leukemia Group B Study 9251. Cancer 2004;100:1438-48. [DOI: 10.1002/cncr.20143] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
26 Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer 2013;119:3672-9. [PMID: 23913575 DOI: 10.1002/cncr.28264] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
27 Mitobe M, Kawamoto K, Suzuki T, Suwabe T, Shibasaki Y, Masuko M, Inoue K, Miyoshi H, Ohshima K, Sone H, Takizawa J. DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction. J Clin Exp Hematop 2021;61:42-7. [PMID: 33551436 DOI: 10.3960/jslrt.20043] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Bortz H, Coutsouvelis J, Corallo CE, Spencer A, Patil S. Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease. J Clin Pharm Ther 2015;40:483-5. [PMID: 26073601 DOI: 10.1111/jcpt.12293] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Opie J, Antel K, Koller A, Novitzky N. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes. Ann Hematol 2020;99:571-8. [PMID: 31955214 DOI: 10.1007/s00277-020-03908-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Sohani AR, Hasserjian RP. Diagnosis of Burkitt Lymphoma and Related High-Grade B-Cell Neoplasms. Surg Pathol Clin 2010;3:1035-59. [PMID: 26839298 DOI: 10.1016/j.path.2010.09.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Chatterjee T, Gupta D, Bharadwaj R, Madan R. Burkittts lymphoma revisited: series of three cases with varied clinical presentation. Indian J Hematol Blood Transfus 2014;30:215-8. [PMID: 25332582 DOI: 10.1007/s12288-014-0334-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Rossi M, Laginestra MA, Gazzola A, Sapienza MR, Pileri SA, Piccaluga PP. Molecular profiling of aggressive lymphomas. Adv Hematol 2012;2012:464680. [PMID: 22190944 DOI: 10.1155/2012/464680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Polizzotto MN, Mccomish JS, Dawson MA, Opat SS, Cole-sinclair MF. Burkitt lymphoma in the setting of common variable immunodeficiency. Ann Hematol 2009;88:819-20. [DOI: 10.1007/s00277-008-0691-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Leich E, Hartmann EM, Christof Burek, Ott G, Rosenwald A. Diagnostic and prognostic significance of gene expression profiling in lymphomas. APMIS 2007;115:1135-46. [DOI: 10.1111/j.1600-0463.2007.apm_867.xml.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
35 Choi MK, Jun HJ, Lee SY, Kim KH, Lim DH, Kim K, Ko YH, Kim WS, Kim SJ. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. Ann Hematol 2009;88:1099-106. [DOI: 10.1007/s00277-009-0729-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
36 Savage KJ. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology Am Soc Hematol Educ Program 2017;2017:578-86. [PMID: 29222307 DOI: 10.1182/asheducation-2017.1.578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
37 Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021;137:374-86. [PMID: 32663292 DOI: 10.1182/blood.2020006926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Patekar M, Gogia A, Tiwari A, Kumar L, Sharma A, Mallick SR, Sharma MC, Thulkar S, Gupta R. Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol. South Asian J Cancer 2018;7:195-9. [PMID: 30112340 DOI: 10.4103/sajc.sajc_230_17] [Reference Citation Analysis]
39 Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. The Lancet 2012;379:1234-44. [DOI: 10.1016/s0140-6736(11)61177-x] [Cited by in Crossref: 325] [Cited by in F6Publishing: 140] [Article Influence: 32.5] [Reference Citation Analysis]
40 Kasamon YL, Brodsky RA, Borowitz MJ, Ambinder RF, Crilley PA, Cho SY, Tsai HL, Smith BD, Gladstone DE, Carraway HE, Huff CA, Matsui WH, Bolaños-Meade J, Jones RJ, Swinnen LJ. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma 2013;54:483-90. [PMID: 22835045 DOI: 10.3109/10428194.2012.715346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
41 Liddell A, Bourgeois SL Jr. Systemic lymphoproliferative diseases. Oral Maxillofac Surg Clin North Am 2008;20:585-96. [PMID: 18940625 DOI: 10.1016/j.coms.2008.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Wright CL, Maly JJ, Zhang J, Knopp MV. Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma. PET Clin 2017;12:63-82. [PMID: 27863567 DOI: 10.1016/j.cpet.2016.08.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
43 Paszkiewicz-Kozik E, Michalski W, Taszner M, Mordak-Domagała M, Romejko-Jarosińska J, Knopińska-Posłuszny W, Najda J, Borawska A, Chełstowska M, Świerkowska M, Dąbrowska-Iwanicka A, Malenda A, Druzd-Sitek A, Konecki R, Kumiega B, Osowiecki M, Ostrowska B, Szpila T, Szymański M, Targoński Ł, Domańska-Czyż K, Popławska L, Giebel S, Lange A, Pluta A, Zaucha JM, Rymkiewicz G, Walewski J. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. Br J Haematol 2022. [PMID: 35362096 DOI: 10.1111/bjh.18166] [Reference Citation Analysis]
44 Wildes TM, Farrington L, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, Fenske TS. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. Ther Adv Hematol 2014;5:3-12. [PMID: 24490019 DOI: 10.1177/2040620713514682] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
45 Magrath IT. Treatment of Burkitt lymphoma in children and adults: Lessons from Africa. Curr Hematol Malig Rep 2006;1:230-40. [PMID: 20425318 DOI: 10.1007/s11899-006-0004-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
46 Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23:777-83. [PMID: 19151788 DOI: 10.1038/leu.2008.344] [Cited by in Crossref: 168] [Cited by in F6Publishing: 144] [Article Influence: 12.9] [Reference Citation Analysis]
47 Lu SC, Shen WL, Cheng YM, Chou CY, Kuo PL. Burkitt'S lymphoma mimicking a primary gynecologic tumor. Taiwan J Obstet Gynecol 2006;45:162-6. [PMID: 17197360 DOI: 10.1016/S1028-4559(09)60217-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
48 Johnson DH, Reske T, Ruiz M. Case report and review of immunodeficiency-associated Burkitt lymphoma. Clin Lymphoma Myeloma Leuk 2015;15:e121-5. [PMID: 25701328 DOI: 10.1016/j.clml.2014.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 Zuze T, Ellis GK, Kasonkanji E, Kaimila B, Nyasosela R, Nyirenda R, Tomoka T, Mulenga M, Chikasema M, Tewete B, Mtangwanika A, Chiyoyola S, Chimzimu F, Kampani C, Mhango W, Nicholas S, Randall C, Montgomery ND, Fedoriw G, Westmoreland KD, Painschab MS, Gopal S. Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. Cancer Med 2020;9:77-83. [PMID: 31705618 DOI: 10.1002/cam4.2631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, Hui C, Prosser I, Lewis ID, Bradstock K, Seymour JF; On behalf of the Australasian Leukaemia and Lymphoma Group. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 2019;60:904-11. [DOI: 10.1080/10428194.2018.1516873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Tholouli E, Watt S, Lucas GS, Burthem J, Yin JA, Cavet J, Greenfield H, Houghton JB. Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome. Blood 2009;114:485-6; author reply 486-7. [PMID: 19589933 DOI: 10.1182/blood-2009-03-213231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Meng X, Min Q, Wang JY. B Cell Lymphoma. Adv Exp Med Biol 2020;1254:161-81. [PMID: 32323276 DOI: 10.1007/978-981-15-3532-1_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
53 Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol 2018;97:255-66. [PMID: 29209924 DOI: 10.1007/s00277-017-3167-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
54 Keller C, Savage DG, Rusta-Villa M, Bhagat G, Alobeid B. Primary Burkitt lymphoma of the uterine corpus. Leuk Lymphoma 2006;47:141-5. [PMID: 16321839 DOI: 10.1080/10428190500144821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Baker PS, Gold KG, Lane KA, Bilyk JR, Katowitz JA. Orbital burkitt lymphoma in immunocompetent patients: a report of 3 cases and a review of the literature. Ophthalmic Plast Reconstr Surg 2009;25:464-8. [PMID: 19935250 DOI: 10.1097/IOP.0b013e3181b80fde] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
56 Boerma EG, van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans JC. Gender and age-related differences in Burkitt lymphoma--epidemiological and clinical data from The Netherlands. Eur J Cancer 2004;40:2781-7. [PMID: 15571961 DOI: 10.1016/j.ejca.2004.09.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
57 Lap CJ, Nassereddine S, Dunleavy K. Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma. Curr Treat Options Oncol 2021;22:60. [PMID: 34097157 DOI: 10.1007/s11864-021-00857-w] [Reference Citation Analysis]
58 Wang L, Wang H, Xia ZJ, Huang HQ, Jiang WQ, Lin TY, Lu Y. Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma. Ann Hematol 2015;94:1645-54. [PMID: 26082333 DOI: 10.1007/s00277-015-2427-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
59 Jo J, Yoon DH, Lee SW, Park CS, Huh J, Lee K, Kang EH, Kim S, Suh C. Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. Blood Res 2014;49:115-9. [PMID: 25025013 DOI: 10.5045/br.2014.49.2.115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
60 Wang CC, Kaplan LD. Clinical management of HIV-associated hematologic malignancies. Expert Rev Hematol 2016;9:361-76. [PMID: 26652941 DOI: 10.1586/17474086.2016.1130615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
61 Roschewski M. Be mindful of the central nervous system in Burkitt lymphoma. Haematologica 2021;106:1785-6. [PMID: 33538157 DOI: 10.3324/haematol.2020.278181] [Reference Citation Analysis]
62 Zhang XX, Xu J, Jiang T, Lu Y. Diagnosis and treatment of primary gastrointestinal Burkitt-like lymphoma in adults. Shijie Huaren Xiaohua Zazhi 2016; 24(4): 612-617 [DOI: 10.11569/wcjd.v24.i4.612] [Reference Citation Analysis]
63 Çiftçiler R, Sevindik ÖG, Tekgündüz AİE, Erkurt MA, Vural F, Turgut B, Kaynar L, Payzın B, Doğu MH, Karakuş V, Altuntaş F, Büyükaşık Y, Demirkan F. Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study. Turk J Haematol 2019;36:169-77. [PMID: 31131598 DOI: 10.4274/tjh.galenos.2019.2019.0008] [Reference Citation Analysis]
64 Levine AM. Challenges in the Management of Burkitt's Lymphoma. Clinical Lymphoma 2002;3:S19-25. [DOI: 10.3816/clm.2002.s.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
65 Sweetenham JW. Highly Aggressive Lymphomas in Adults. Hematology/Oncology Clinics of North America 2008;22:965-78. [DOI: 10.1016/j.hoc.2008.07.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
66 Barta SK. To be or not to be HIV+, that is no longer the question. Blood 2015;126:124-6. [PMID: 26160183 DOI: 10.1182/blood-2015-05-645721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Or C, Kirker AW, Rasmussen S, Villa D, Gerrie AS, Forooghian F. Double-hit vitreoretinal lymphoma. Can J Ophthalmol 2014;49:e73-6. [PMID: 24862789 DOI: 10.1016/j.jcjo.2014.03.012] [Reference Citation Analysis]
68 de Leval L, Hasserjian RP. Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma. Hematology/Oncology Clinics of North America 2009;23:791-827. [DOI: 10.1016/j.hoc.2009.04.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
69 Peterson C, Lester DR, Sanger W. Burkitt's Lymphoma in Early Pregnancy. JCO 2010;28:e136-8. [DOI: 10.1200/jco.2009.24.6355] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
70 Casulo C, Friedberg J. Treating Burkitt Lymphoma in Adults. Curr Hematol Malig Rep 2015;10:266-71. [DOI: 10.1007/s11899-015-0263-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
71 Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther 2017;8:11-29. [PMID: 28096698 DOI: 10.2147/AHMT.S94170] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
72 Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 2010;92:732-43. [PMID: 21120644 DOI: 10.1007/s12185-010-0728-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
73 Zayac AS, Olszewski AJ. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. Leuk Lymphoma 2020;61:1784-96. [PMID: 32255708 DOI: 10.1080/10428194.2020.1747068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
74 Tadipatri R, Gonzalez D, Muley S, Fonkem E, Azadi A. A Rare Case of Burkitt's Lymphoma Presenting With Features Mimicking Vogt-Koyanagi-Harada Disease. Cureus 2021;13:e17659. [PMID: 34646701 DOI: 10.7759/cureus.17659] [Reference Citation Analysis]
75 Testa AC, De Blasis I, Di Legge A, Belli P, Hohaus S, Ferrandina G. Burkitt's lymphoma of the breast metastatic to the ovary diagnosed during pregnancy. Ultrasound Obstet Gynecol 2013;42:364-6. [DOI: 10.1002/uog.12533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
76 Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, Lacruz J, Valencia E, Santos J, Rodríguez-Arrondo F, Pintado V; Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr 2007;44:167-73. [PMID: 17117144 DOI: 10.1097/QAI.0b013e31802bb5d0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
77 Baek DW, Lee JM, Kim J, Cho HJ, Moon JH, Sohn SK. Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. Expert Rev Hematol 2021;14:765-75. [PMID: 34313508 DOI: 10.1080/17474086.2021.1960817] [Reference Citation Analysis]
78 de Vos S. Historical Overview and Current State of Art in Diagnosis and Treatment of Hodgkin's and Non-Hodgkin's Lymphoma. PET Clinics 2006;1:203-17. [DOI: 10.1016/j.cpet.2006.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
79 Miralles P, Berenguer J, Ribera Santasusana JM, Calvo F, Díaz Mediavilla J, Luis Díez-martín J, Gomez Codina J, López Aldeguer J, Rubio R, Santos J, Valencia E. Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y el tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. Medicina Clínica 2008;130:300-11. [DOI: 10.1157/13116574] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
80 John Wiley & Sons, Ltd. Current Awareness in Hematological Oncology. Hematol Oncol 2003;21:43-50. [DOI: 10.1002/hon.706] [Reference Citation Analysis]
81 Barnes J, Lacasce A, Feng Y, Toomey C, Neuberg D, Michaelson J, Hochberg E, Abramson J. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Annals of Oncology 2011;22:1859-64. [DOI: 10.1093/annonc/mdq677] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 8.0] [Reference Citation Analysis]
82 Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol. 2004;15:1072-1078. [PMID: 15205201 DOI: 10.1093/annonc/mdh262] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
83 Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L; AIDS Malignancy Consortium. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood 2015;126:160-6. [PMID: 25957391 DOI: 10.1182/blood-2015-01-623900] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
84 Thomas DA, O'Brien S, Faderl S, Manning JT Jr, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep 2011;6:58-66. [PMID: 21191675 DOI: 10.1007/s11899-010-0076-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
85 Miralles P, Navarro JT, Berenguer J, Gómez Codina J, Kwon M, Serrano D, Díez-Martín JL, Villà S, Rubio R, Menárguez J, Ribera Santasusana JM. GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. Med Clin (Barc) 2018;151:39.e1-39.e17. [PMID: 29357988 DOI: 10.1016/j.medcli.2017.11.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Mohamedbhai SG, Sibson K, Marafioti T, Kayani I, Lowry L, Goldstone AH, Linch DC, Ardeshna KM. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%: Rituximab with CODOX-M/IVAC in B-NHL with High Proliferation. British Journal of Haematology 2011;152:175-81. [DOI: 10.1111/j.1365-2141.2010.08447.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
87 Lin Y, Pan YH, Li MK, Zong XD, Pan XM, Tan SY, Guo YW. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report. World J Gastroenterol 2021; 27(45): 7844-7854 [PMID: 34963746 DOI: 10.3748/wjg.v27.i45.7844] [Reference Citation Analysis]
88 Roschewski M. The balancing act in Burkitt lymphoma. Blood 2021;137:289-91. [PMID: 33475738 DOI: 10.1182/blood.2020008091] [Reference Citation Analysis]
89 Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, De Chiara A, Morelli E, Capobianco G, Becchimanzi C, Volzone F, Saggese M, Marcacci G, De Filippi R, Vitolo U, Pinto A. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma: RD-CODOX-M/IVAC in adult BL and BL/DLBCL. British Journal of Haematology 2012;156:234-44. [DOI: 10.1111/j.1365-2141.2011.08947.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
90 Ge X, Chen J, Li L, Ding P, Wang Q, Zhang W, Li L, Lv X, Zhou D, Jiang Z, Zeng H, Xu Y, Hou Y, Hu W. Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis. Cell Death Dis 2018;10:8. [PMID: 30584254 DOI: 10.1038/s41419-018-1259-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
91 Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom? Blood Reviews 2012;26:97-106. [DOI: 10.1016/j.blre.2011.12.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
92 Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:2402-11. [PMID: 27080498 DOI: 10.1016/S0140-6736(15)01317-3] [Cited by in Crossref: 106] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
93 Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, Eickhoff JC, Kahl BS. A 5-Drug Regimen Maximizing the Dose of Cyclophosphamide is Effective Therapy for Adult Burkitt or Burkitt-like Lymphomas. Cancer Investigation 2009;25:87-93. [DOI: 10.1080/07357900701205507] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
94 Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, Pizzolo G. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol 2012;87:22-5. [PMID: 22086870 DOI: 10.1002/ajh.22189] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
95 Musekwa E, Chapanduka ZC, Bassa F, Kruger M. An 8-year retrospective study of adult and paediatric Burkitt’s lymphoma at Tygerberg Hospital, South Africa. South African Journal of Oncology 2020;4. [DOI: 10.4102/sajo.v4i0.93] [Reference Citation Analysis]
96 Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED; Cancer Leukemia Group B. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758-65. [PMID: 22133772 DOI: 10.3324/haematol.2011.056531] [Cited by in Crossref: 120] [Cited by in F6Publishing: 122] [Article Influence: 10.9] [Reference Citation Analysis]
97 Kandil E, Safah H, Noureldine S, Abdel Khalek M, Waddadar J, Goswami M, Friedlander P. Burkitt-like lymphoma arising in the thyroid gland. Am J Med Sci 2012;343:103-5. [PMID: 22143121 DOI: 10.1097/MAJ.0b013e318235af39] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
98 Mukhtar F, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, Tran TV, Zgibor JC, Luu HN. Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013. Int J Cancer 2017;140:1494-502. [PMID: 28006853 DOI: 10.1002/ijc.30576] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
99 Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM. Burkitt Lymphoma International Prognostic Index. J Clin Oncol 2021;39:1129-38. [PMID: 33502927 DOI: 10.1200/JCO.20.03288] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Teofili L, Izzi I, Nuzzolo ER, Scoppettuolo G, Torti L, Rossi M, de Gaetano Donati K. Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration. Mediterr J Hematol Infect Dis 2012;4:e2012062. [PMID: 23170191 DOI: 10.4084/MJHID.2012.062] [Reference Citation Analysis]
101 Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group., Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248-60. [PMID: 18612102 DOI: 10.1182/blood-2008-03-145128] [Cited by in Crossref: 146] [Cited by in F6Publishing: 126] [Article Influence: 10.4] [Reference Citation Analysis]
102 Gregory GP, Dickinson M, Yannakou CK, Wong J, Blombery P, Corboy G, Kats L, Crozier TME, Kumar B, Prince HM, Opat SS, Shortt J. Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS. Hemasphere 2019;3:e187. [PMID: 31723826 DOI: 10.1097/HS9.0000000000000187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
103 Saleh K, Michot JM, Camara-Clayette V, Vassetsky Y, Ribrag V. Burkitt and Burkitt-Like Lymphomas: a Systematic Review. Curr Oncol Rep 2020;22:33. [PMID: 32144513 DOI: 10.1007/s11912-020-0898-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
104 Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol 2020;38:2519-29. [PMID: 32453640 DOI: 10.1200/JCO.20.00303] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
105 Zhang XX, Sun CD, Song Y, Zhang BY, Lu Y, Zhao W, Hu JL. Adult Burkitt-like lymphoma of the ileum: a case report and review of the literature. Shijie Huaren Xiaohua Zazhi 2010; 18(36): 3930-3933 [DOI: 10.11569/wcjd.v18.i36.3930] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Gerecitano J, Straus DJ. Treatment of Burkitt lymphoma in adults. Expert Review of Anticancer Therapy 2014;6:373-81. [DOI: 10.1586/14737140.6.3.373] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
107 Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica 2021;106:1932-42. [PMID: 33538152 DOI: 10.3324/haematol.2020.270876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
108 Ferry JA. Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006;11:375-383. [PMID: 16614233 DOI: 10.1634/theoncologist.11-4-375] [Cited by in Crossref: 200] [Cited by in F6Publishing: 161] [Article Influence: 12.5] [Reference Citation Analysis]
109 Pagano L, Caira M, Valentini CG, Fianchi L. Clinical aspects and therapy of sporadic burkitt lymphoma. Mediterr J Hematol Infect Dis 2009;1:e2009030. [PMID: 21416007 DOI: 10.4084/MJHID.2009.030] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
110 Crombie JL, LaCasce AS. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. Front Oncol 2019;9:109. [PMID: 30899698 DOI: 10.3389/fonc.2019.00109] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
111 Nicola MD, Carlo-stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults: Short-term Regimen for Adult Burkitt's Lymphoma. British Journal of Haematology 2004;126:815-20. [DOI: 10.1111/j.1365-2141.2004.05141.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
112 Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 2014;165:102-11. [PMID: 24428673 DOI: 10.1111/bjh.12736] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 6.3] [Reference Citation Analysis]
113 Pasricha SR, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D'Rozario J, Lowenthal R, Reed K, Spencer A. A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer 2008;113:3192-8. [PMID: 18932253 DOI: 10.1002/cncr.23915] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
114 Kwong YL, Yeung DY, Chan JC. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 2009;88:193-201. [PMID: 19050889 DOI: 10.1007/s00277-008-0645-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
115 Sakumura M, Tajiri K, Miwa S, Nagata K, Kawai K, Miyazono T, Arita K, Wada A, Murakami J, Sugiyama T. Hepatic Sinusoidal Obstruction Syndrome Induced by Non-transplant Chemotherapy for Non-Hodgkin Lymphoma. Intern Med 2017;56:395-400. [PMID: 28202860 DOI: 10.2169/internalmedicine.56.7669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
116 Wang GB, Xu GL, Luo GY, Shan HB, Li Y, Gao XY, Li JJ, Zhang R. Primary intestinal non-Hodgkin's lymphoma: A clinicopathologic analysis of 81 patients. World J Gastroenterol 2011; 17(41): 4625-4631 [PMID: 22147970 DOI: 10.3748/wjg.v17.i41.4625] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
117 Jacobsen E, Lacasce A. Update on the therapy of highly aggressive non-Hodgkin’s lymphoma. Expert Opinion on Biological Therapy 2006;6:699-708. [DOI: 10.1517/14712598.6.7.699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Mitra S, Mehta A, Gupta SK, Sharma A, Louis AR, Sharma MK, Saxena U, Simson DK, Dewan A. Primary Gastric Burkitt's Lymphoma. Rare Tumors 2014;6:5300. [PMID: 25568743 DOI: 10.4081/rt.2014.5300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Tzachanis D, Dewar R, Luptakova K, Chang JD, Joyce RM. Primary cardiac burkitt lymphoma presenting with abdominal pain. Case Rep Hematol 2014;2014:687598. [PMID: 25431699 DOI: 10.1155/2014/687598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
120 Dunleavy K. Approach to the Diagnosis and Treatment of Adult Burkitt's Lymphoma. JOP 2018;14:665-71. [DOI: 10.1200/jop.18.00148] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 4.8] [Reference Citation Analysis]
121 Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-205. [PMID: 12973843 DOI: 10.1002/cncr.11628] [Cited by in Crossref: 111] [Cited by in F6Publishing: 95] [Article Influence: 5.8] [Reference Citation Analysis]
122 Jiang M, Zhu J, Guan YS, Zou LQ. Primary central nervous system burkitt lymphoma with non-immunoglobulin heavy chain translocation in right ventricle: case report. Pediatr Hematol Oncol 2011;28:454-8. [PMID: 21615246 DOI: 10.3109/08880018.2011.566599] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
123 Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program 2008;:341-8. [PMID: 19074108 DOI: 10.1182/asheducation-2008.1.341] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
124 Cheung MC, Imrie KR, Leitch HA, Park-wyllie LY, Buckstein R, Antoniou T, Loutfy MR. Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma. Ann Hematol 2007;86:631-8. [DOI: 10.1007/s00277-007-0284-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
125 Bociek RG. Adult Burkitt's Lymphoma. Clinical Lymphoma 2005;6:11-20. [DOI: 10.3816/clm.2005.n.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
126 Doval DC, Bhurani D, Nair R, Gujral S, Malhotra P, Ramanan G, Mohan R, Biswas G, Dattatreya S, Agarwal S, Pendharkar D, Julka PK, Advani SH, Dhaliwal RS, Tayal J, Sinha R, Kaur T, Rath GK. Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade). Indian J Med Paediatr Oncol 2017;38:51-8. [PMID: 28469337 DOI: 10.4103/0971-5851.203500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
127 Kasamon YL, Swinnen LJ. Treatment advances in adult Burkitt lymphoma and leukemia: . Current Opinion in Oncology 2004;16:429-35. [DOI: 10.1097/00001622-200409000-00003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
128 Castillo JJ, Nadeem O. Improving the accuracy in prognosis for Burkitt lymphoma patients. Expert Review of Anticancer Therapy 2014;14:125-7. [DOI: 10.1586/14737140.2014.866042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
129 Lewis H, Mahdi AJ, Rowntree C. Bilateral subdural hygromas following administration of intrathecal methotrexate chemotherapy. BMJ Case Rep 2015;2015:bcr2014205059. [PMID: 26002663 DOI: 10.1136/bcr-2014-205059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
130 Frick M, Dörken B, Lenz G. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. Best Practice & Research Clinical Haematology 2012;25:3-12. [DOI: 10.1016/j.beha.2012.01.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
131 Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 2009;9:307-10. [PMID: 19717381 DOI: 10.3816/CLM.2009.n.060] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
132 Hashimoto K, Kobayashi Y, Asakura Y, Mori M, Azuma T, Maruyama D, Kim S, Watanabe T, Tobinai K. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leukemia & Lymphoma 2010;51:1816-21. [DOI: 10.3109/10428194.2010.506569] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
133 Casulo C, Friedberg JW. Burkitt lymphoma- a rare but challenging lymphoma. Best Pract Res Clin Haematol 2018;31:279-84. [PMID: 30213397 DOI: 10.1016/j.beha.2018.07.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
134 Hadžisejdić I, Babarović E, Vranić L, Duletić Načinović A, Lučin K, Krašević M, Jonjić N. Unusual presentation of plasmablastic lymphoma involving ovarian mature cystic teratoma: a case report. Diagn Pathol 2017;12:83. [PMID: 29187222 DOI: 10.1186/s13000-017-0672-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
135 Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, Ralli R, Cullinane C, Schmitt CA, Reimann M, Hall MN, Wall M, Hannan RD, Pearson RB, McArthur GA, Johnstone RW. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 2013;121:2964-74. [PMID: 23403624 DOI: 10.1182/blood-2012-08-446096] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
136 Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Douer D. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 2016;95:2009-15. [PMID: 27542957 DOI: 10.1007/s00277-016-2795-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
137 Phillips EH, Burton C, Kirkwood AA, Barrans S, Lawrie A, Rule S, Patmore R, Pettengell R, Ardeshna KM, Montoto S, Paneesha S, Clifton‐hadley L, Linch DC, Mcmillan AK. Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial. eJHaem 2020;1:133-41. [DOI: 10.1002/jha2.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
138 Hübel K, Montoto S. Other T- and B-Aggressive Lymphomas and Lymphomas Associated with HIV. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 647-51. [DOI: 10.1007/978-3-030-02278-5_87] [Reference Citation Analysis]
139 Yoon DH, Sohn BS, Oh SY, Lee WS, Lee SM, Yang DH, Huh J, Suh C. Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). Oncotarget 2017;8:13367-74. [PMID: 28076329 DOI: 10.18632/oncotarget.14531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
140 Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am 2008;46:175-98, vii. [PMID: 18619375 DOI: 10.1016/j.rcl.2008.03.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
141 Kian TC, Miriam T, Richard Q, Peng YS, Li LE, Ivy S, Hwan-cheong TL, Hua LH, Thye LS. Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leukemia & Lymphoma 2009;49:824-7. [DOI: 10.1080/10428190701882948] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
142 Jack A. XI. Distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma. Annals of Oncology 2011;22:iv61-3. [DOI: 10.1093/annonc/mdr177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
143 Sanders L, Jayne S, Kennedy B, Miall F, Aukema SM, Siebert R, Wagner SD, Dyer MJ. A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome. Case Rep Hematol 2014;2014:120714. [PMID: 25349747 DOI: 10.1155/2014/120714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
144 Jang S, Yoon DH, Kim S, Yoon S, Kim DY, Park C, Huh J, Lee S, Lee DH, Ryu J, Suh C. A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience. Ann Hematol 2012;91:1917-22. [DOI: 10.1007/s00277-012-1531-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
145 Goldstein JS, Switchenko JM, Behera M, Flowers CR, Koff JL. Insurance status impacts overall survival in Burkitt lymphoma. Leuk Lymphoma 2019;60:3225-34. [PMID: 31274033 DOI: 10.1080/10428194.2019.1623884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
146 Xiao J, Du S, Dai G, Gao G, Yang D, Zhao H. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. Sci Rep 2017;7:1905. [PMID: 28507339 DOI: 10.1038/s41598-017-02086-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
147 Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood 2021;137:743-50. [PMID: 33171490 DOI: 10.1182/blood.2019004099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Kim YS, Lee JK, Choi KY, Jang JW. Spinal Burkitt's Lymphoma Mimicking Dumbbell Shape Neurogenic Tumor: A Case Report and Review of the Literature. Korean J Spine. 2015;12:221-224. [PMID: 26512290 DOI: 10.14245/kjs.2015.12.3.221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
149 Chen MT, Pan F, Chen YC, Zhang W, Lv HJ, Wang Z, Hong HM, Fang XJ, Wang YW, Pan T, Zou LQ, Guo HQ, Xie K, Chen LM, Li XQ, Yao YY, Chen ZG, Weng HW, Li XD, Shen YY, Zhou H, Xue HW, Zhang HL, Huang H, Lin TY. A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study. BMC Cancer 2022;22:45. [PMID: 34996395 DOI: 10.1186/s12885-021-09144-1] [Reference Citation Analysis]
150 Wong Doo N, White VM, Martin K, Bassett JK, Prince HM, Harrison SJ, Jefford M, Winship I, Millar JL, Milne RL, Seymour JF, Giles GG. The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. Cancers (Basel) 2019;11:E928. [PMID: 31269764 DOI: 10.3390/cancers11070928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
151 Pentak D. Evaluation of the physicochemical properties of liposomes as potential carriers of anticancer drugs: spectroscopic study. J Nanopart Res 2016;18. [DOI: 10.1007/s11051-016-3427-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
152 Fujiwara H, Odawara J, Hayama B, Takanashi Y, Iwama K, Yamakura M, Takeuchi M, Matsue K. Gross hematopyuria presenting as a first symptom due to the bladder infiltration of extranodal Burkitt's lymphoma. J Clin Oncol 2010;28:e252-3. [PMID: 20421542 DOI: 10.1200/JCO.2009.26.0398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
153 Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1087-1097. [PMID: 16092591 DOI: 10.4065/80.8.1087] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 5.7] [Reference Citation Analysis]
154 Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D, Raffoux E, Lengline E, Chevret S, Darmon M, Azoulay E. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One 2013;8:e55870. [PMID: 23457485 DOI: 10.1371/journal.pone.0055870] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
155 Bodrog A, Zhang B, Liu L, Casulo C, Bennett JM. A case of Burkitt Leukemia: Revisiting the prognostic value of lactate dehydrogenase. Leuk Res 2020;89:106295. [PMID: 31924584 DOI: 10.1016/j.leukres.2019.106295] [Reference Citation Analysis]
156 Alsharif R, Dunleavy K. Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements. Hematology/Oncology Clinics of North America 2019;33:587-96. [DOI: 10.1016/j.hoc.2019.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
157 Galicier L, Fieschi C, Borie R, Meignin V, Daniel M, Gérard L, Oksenhendler E. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 2007;110:2846-54. [DOI: 10.1182/blood-2006-10-051771] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
158 Ma'koseh M, Amarin R, Tamimi F, Sharaf B, Abufara A, Shahin O, Manassra MKM, Halahleh K. Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan. Blood Res 2021;56:279-84. [PMID: 34880141 DOI: 10.5045/br.2021.2021116] [Reference Citation Analysis]
159 Koffi GK, Tolo A, Nanho DC, N'dathz E, Kouassi MY, N'Diaye FD, Kouakou B, Meité N, Ayemou R, Sekongo M, Kouehion P, Meité M, Tea ND, Sangaré A, Sanogo I. Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire. Int J Hematol 2010;91:838-43. [PMID: 20480270 DOI: 10.1007/s12185-010-0591-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
160 Lu J, Tan H, Li B, Chen S, Xu L, Zou Y. Status and prognostic nomogram of patients with Burkitt lymphoma. Oncol Lett 2020;19:972-84. [PMID: 31897210 DOI: 10.3892/ol.2019.11155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Smyth L, Browne PV, Conneally E, Flynn C, Hayden P, Jeffers M, O'Brien D, Quinn F, Kelly J, Perera M, Crotty GM, Leahy M, Hennessy B, Jackson F, Ryan M, Vandenberghe E. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL. Ir J Med Sci 2016;185:773-7. [PMID: 25843016 DOI: 10.1007/s11845-015-1288-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
162 Jacobson C, Lacasce A. How I treat Burkitt lymphoma in adults. Blood 2014;124:2913-20. [DOI: 10.1182/blood-2014-06-538504] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
163 Jack A, Barrans S. Recent advances in the understanding of aggressive B-cell lymphomas. Current Diagnostic Pathology 2004;10:360-73. [DOI: 10.1016/j.cdip.2004.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
164 Nie M, Wang Y, Bi XW, Xia Y, Sun P, Liu PP, Li ZM, Jiang WQ. Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis. Ann Hematol 2016;95:19-26. [PMID: 26423805 DOI: 10.1007/s00277-015-2501-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
165 Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580. [PMID: 16502413 DOI: 10.1002/cncr.21776] [Cited by in Crossref: 362] [Cited by in F6Publishing: 297] [Article Influence: 22.6] [Reference Citation Analysis]
166 Linch DC. Burkitt lymphoma in adults: Review. British Journal of Haematology 2012;156:693-703. [DOI: 10.1111/j.1365-2141.2011.08877.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
167 Hong J, Kim SJ, Ahn JS, Song MK, Kim YR, Lee HS, Yhim HY, Yoon DH, Kim MK, Oh SY, Park Y, Mun YC, Do YR, Ryoo HM, Lee JJ, Lee JH, Kim WS, Suh C. Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Cancer Res Treat 2015;47:173-81. [PMID: 25544581 DOI: 10.4143/crt.2014.055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
168 Chehab BM, Schulz TK, Nassif II. Adult Burkitt-like lymphoma of the colon: a case report and a review of the literature. Gastrointest Endosc. 2008;67:1204-1206. [PMID: 18243189 DOI: 10.1016/j.gie.2007.10.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
169 Choi KA, Lee JE, Kim Y, Kim DJ, Kim K, Ko YH, Oh HY, Kim WS, Huh W. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann Hematol 2009;88:639-45. [DOI: 10.1007/s00277-008-0642-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
170 Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010;107:163-224. [PMID: 20399964 DOI: 10.1016/S0065-230X(10)07006-5] [Cited by in Crossref: 162] [Cited by in F6Publishing: 106] [Article Influence: 13.5] [Reference Citation Analysis]
171 Millot F, Barboteau MA, Loyer-Lecestre MJ, Brizard F, Levillain P, Guilhot F. Endoscopic diagnosis of childhood Burkitt's lymphoma of the colon. J Clin Oncol 2010;28:e374-5. [PMID: 20406938 DOI: 10.1200/JCO.2009.25.6990] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
172 Telio D, Fernandes K, Ma C, Tsang R, Keating A, Crump M, Kuruvilla J. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma 2012;53:836-41. [PMID: 22136378 DOI: 10.3109/10428194.2011.643404] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
173 Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M, Zanet E, Lleshi A, Canzonieri V, Bulian P, Tirelli U. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2010;116:1495-501. [PMID: 20108270 DOI: 10.1002/cncr.24922] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
174 Canova F, Marino D, Trentin C, Soldà C, Ghiotto C, Aversa SML. Intrathecal chemotherapy in lymphomatous meningitis. Critical Reviews in Oncology/Hematology 2011;79:127-34. [DOI: 10.1016/j.critrevonc.2010.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
175 Kalinyak JE, Kong CS, McDougall IR. Burkitt's lymphoma presenting as a rapidly growing thyroid mass. Thyroid 2006;16:1053-7. [PMID: 17042693 DOI: 10.1089/thy.2006.16.1053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
176 Pettengell R, Aapro M, Brusamolino E, Caballero D, Coiffier B, Pfreundschuh M, Trneny M, Walewski J. Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. Clin Drug Investig 2009;29:491-513. [PMID: 19591512 DOI: 10.2165/00044011-200929080-00001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
177 Slack GW, Hsi ED, Gascoyne RD. Diffuse Aggressive B-Cell Lymphomas. Hematopathology. Elsevier; 2012. pp. 261-92. [DOI: 10.1016/b978-1-4377-2606-0.00008-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
178 Mcmillan A, Ardeshna KM, Cwynarski K, Lyttelton M, Mckay P, Montoto S. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol 2013. [DOI: 10.1111/bjh.12509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
179 Moleti ML, Testi AM, Giona F, Malandruccolo L, Pescarmona E, Martino P, Paoloni F, Barberi W, Palumbo G, Mandelli F, Foa R. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma 2007;48:551-9. [PMID: 17454598 DOI: 10.1080/10428190601078944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
180 Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009-3020. [PMID: 15265787 DOI: 10.1182/blood-2004-02-0405] [Cited by in Crossref: 340] [Cited by in F6Publishing: 285] [Article Influence: 18.9] [Reference Citation Analysis]
181 Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V; GELA., GOELAMS. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005;16:1928-35. [PMID: 16284057 DOI: 10.1093/annonc/mdi403] [Cited by in Crossref: 85] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]